Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07560865 · ClinicalTrials.gov registry record · Phase 1
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT07560865 is a Phase 1 study that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 9 participants.
The verdict
NCT07560865, a Phase 1 study, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally
Interventions
- BIOLOGICAL FT536
- PROCEDURE Biopsy/ Intratumoral Injection/ Gross Tumor Resection
- DIAGNOSTIC_TEST Blood/ Cerebrospinal Fluid/ Tumor Pathology
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07560865
The ClinicalTrials.gov registry entry for NCT07560865 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FT536 is the first listed.
NCT07560865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07560865 about?
NCT07560865 is a clinical study titled "First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma". This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable...
What is the current status of trial NCT07560865?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-04-23. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT07560865?
The interventions under investigation include: FT536 (BIOLOGICAL), Biopsy/ Intratumoral Injection/ Gross Tumor Resection (PROCEDURE), Blood/ Cerebrospinal Fluid/ Tumor Pathology (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07560865?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.